Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologai - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumabas - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologai - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

novartis europharm limited - ranibizumabas - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - oftalmologai - lucentis yra nurodyta suaugusiems:gydymo neovascular (šlapias) su amžiumi susijusios geltonosios dėmės degeneracija (amd)gydyti regėjimo sutrikimus dėl choroidal neovascularisation (cnv)gydyti regėjimo sutrikimus dėl diabetinės geltonosios dėmės edema (dme)gydyti regėjimo sutrikimus dėl geltonosios dėmės edema antrinio tinklainės venų užakimas (filialas rvo ar centrinio rvo).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologai - eylea yra nurodyta suaugusiųjų gydymas:neovascular (šlapias) su amžiumi susijusios geltonosios dėmės degeneracija (amd);regos sutrikimų, dėl geltonosios dėmės edema antrinio tinklainės venų užakimas (filialas rvo ar centrinio rvo);regos sutrikimų, dėl diabetinės geltonosios dėmės edema (dme);regos sutrikimų, dėl trumparegiško choroidal neovascularisation (trumparegis cnv).

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

viatris limited - aflibercept - macular edema; retinal vein occlusion; diabetic retinopathy; myopia, degenerative; diabetes complications - oftalmologai - yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (amd) (see section 5. 1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo) (see section 5. 1),visual impairment due to diabetic macular oedema (dme) (see section 5. 1),visual impairment due to myopic choroidal neovascularisation (myopic cnv) (see section 5.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

rotterdam biologics b.v. - bevacizumabas - drėgnas makulos degeneravimas - oftalmologai - treatment of neovascular (wet) age-related macular degeneration (amd).